Land: Írland
Tungumál: enska
Heimild: HPRA (Health Products Regulatory Authority)
CALCITRIOL
Roche Products Limited
CALCITRIOL
0.25 Microgram
Capsules, Soft
Product subject to prescription which may be renewed (B)
Authorised
0000-00-00
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Rocaltrol 0.25 microgram Soft Capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 0.25 micrograms of calcitriol. Each capsule contains up to 4.37mg of sorbitol. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Capsule, soft One length brown-orange to red-orange opaque and the other white to grey-yellow or grey-orange opaque. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Rocaltrol is indicated for the correction of the abnormalities of calcium and phosphate metabolism in patients with renal osteodystrophy. Rocaltrol is also indicated for the treatment of established post-menopausal osteoporosis. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The dose of Rocaltrol should be carefully adjusted for each patient according to the biological response so as to avoid hypercalcaemia. The effectiveness of treatment depends in part on an adequate daily intake of calcium, which should be augmented by dietary changes or supplements if necessary. The capsules should be swallowed with a little water. _ADULTS_ _RENAL OSTEODYSTROPHY_ The initial daily dose is 0.25 mcg of Rocaltrol. In patients with normal or only slightly reduced calcium levels, doses of 0.25 mcg every other day are sufficient. If no satisfactory response in the biochemical parameters and clinical manifestations of the disease is observed within 2 - 4 weeks, the daily dosage may be increased by 0.25 mcg at 2 - 4 week intervals. During this period, serum calcium levels should be determined at least twice weekly. Should the serum calcium levels rise to 1 mg/100 ml (250 µmol/l) above normal (9 to 11 mg/100 ml or 2250 – 2750 µmol/l), or serum creatinine rises to > 120 µmol/l, treatment with Rocaltrol should be Lestu allt skjalið